PEN vs. WST, BAX, SWAV, PODD, SOLV, TFX, GMED, MMSI, INSP, and HAE
Should you be buying Penumbra stock or one of its competitors? The main competitors of Penumbra include West Pharmaceutical Services (WST), Baxter International (BAX), Shockwave Medical (SWAV), Insulet (PODD), Solventum (SOLV), Teleflex (TFX), Globus Medical (GMED), Merit Medical Systems (MMSI), Inspire Medical Systems (INSP), and Haemonetics (HAE). These companies are all part of the "surgical & medical instruments" industry.
Penumbra (NYSE:PEN) and West Pharmaceutical Services (NYSE:WST) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, media sentiment, analyst recommendations, community ranking, profitability, risk, valuation, institutional ownership and dividends.
88.9% of Penumbra shares are owned by institutional investors. Comparatively, 93.9% of West Pharmaceutical Services shares are owned by institutional investors. 5.0% of Penumbra shares are owned by company insiders. Comparatively, 0.5% of West Pharmaceutical Services shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Penumbra has a beta of 0.57, suggesting that its stock price is 43% less volatile than the S&P 500. Comparatively, West Pharmaceutical Services has a beta of 1.05, suggesting that its stock price is 5% more volatile than the S&P 500.
In the previous week, West Pharmaceutical Services had 3 more articles in the media than Penumbra. MarketBeat recorded 9 mentions for West Pharmaceutical Services and 6 mentions for Penumbra. West Pharmaceutical Services' average media sentiment score of 1.06 beat Penumbra's score of 0.89 indicating that West Pharmaceutical Services is being referred to more favorably in the news media.
West Pharmaceutical Services has a net margin of 19.42% compared to Penumbra's net margin of 8.52%. West Pharmaceutical Services' return on equity of 20.57% beat Penumbra's return on equity.
West Pharmaceutical Services has higher revenue and earnings than Penumbra. West Pharmaceutical Services is trading at a lower price-to-earnings ratio than Penumbra, indicating that it is currently the more affordable of the two stocks.
Penumbra currently has a consensus target price of $300.64, indicating a potential upside of 58.67%. West Pharmaceutical Services has a consensus target price of $435.20, indicating a potential upside of 31.32%. Given Penumbra's higher possible upside, equities analysts plainly believe Penumbra is more favorable than West Pharmaceutical Services.
Penumbra received 531 more outperform votes than West Pharmaceutical Services when rated by MarketBeat users. Likewise, 80.43% of users gave Penumbra an outperform vote while only 55.74% of users gave West Pharmaceutical Services an outperform vote.
Summary
West Pharmaceutical Services beats Penumbra on 12 of the 18 factors compared between the two stocks.
Get Penumbra News Delivered to You Automatically
Sign up to receive the latest news and ratings for PEN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PEN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Penumbra Competitors List
Related Companies and Tools
